## ROL: Rollins, Inc. - XLY: Consumer Cyclical

### Executive Summary

No thesis match: MRS_20 -1.5% below STRENGTH zone (4.0-10.0%); PEG 3.91 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($57.37)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. BNP Paribas Exane Initiates Rollins at Neutral With $65 Price Target**
- Source: marketscreener.com | 20260106T141630 | Neutral | Relevance: 100%
- BNP Paribas Exane has initiated coverage of Rollins, Inc. with a "Neutral" rating and set a price target of $65. This news comes amidst other recent analyst adjustments for Rollins, including RBC raising its target to $70 and Morgan Stanley upgrading the stock to "Overweight." The article also briefly outlines Rollins' business segments, noting it is a leading provider of pest control services.

**2. Insect Pest Control Market to Reach USD 32.1 Billion by 2032 | CAGR**
- Source: openPR.com | 20260105T122602 | Somewhat-Bullish | Relevance: 95%
- The global insect pest control market is projected to reach USD 32.1 billion by 2032, growing at a CAGR of 6.5% during 2025-2032, up from USD 18.1 billion in 2023. Key drivers include increasing food security concerns, rising productivity requirements, and the growing prevalence of pest infestations, with North America and Asia-Pacific leading market growth. Major players like Bayer, BASF, FMC, Sumitomo, Rentokil, and Rollins are contributing to this expansion through innovative solutions and strategic acquisitions.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Morgan Stanley | $72 | $58 | +24% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Morgan Stanley | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 7 ($3296.08M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 24.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Vanguard Group Inc: 7.6% (+4.2%)
- Blackrock Inc.: 6.0% (+1.2%)
- State Street Corpora: 2.5% (+1.4%)
- Kayne Anderson Rudni: 2.0% (-2.8%)
- Geode Capital Manage: 2.0% (+1.7%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-1.7% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $3296M sold (7 transactions in 90 days).
3. Valuation stretched: PEG 3.9x requires aggressive growth execution.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.91 signals overvaluation risk, limited margin of safety. Forward P/E 46.5x stretched relative to 12% growth. Quality metrics strong (ROE 36%, ROA 15%). Analyst sentiment positive (1 raises, avg +24%, $71 target (+20%)). Insider selling cluster ($3296.1M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $28.6B |
| Beta | 0.79 |
| 52W Range | $45.34 - $61.84 |
| Short Interest | 3.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.91 |
| Forward P/E | 46.5 |
| Current P/E | 52.1 |
| YoY Growth | 12.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 0.2% to -1.5% (-1.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.5pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.04x) but short-term weakness (below SMA20). RSI neutral at 47. OFD pattern: +MLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.49% (CS: 23) | Neutral |
| RSI_14 | 47.3 | Neutral |
| MACD Histogram | -0.20 | Bearish |
| vs SMA20 | 0.993x | Below |
| vs SMA50 | 1.003x | Above |
| vs SMA200 | 1.042x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $59.51
- **Stop Loss:** $57.37 (3.6% risk)
- **Target:** $61.65 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 514
- **Position Value:** $30,588.14
- **Portfolio %:** 30.59%
- **Risk Dollars:** $1,100.00
- **Risk Per Trade:** 1.10%
- **Modifiers:** L1 110% | L2 100% | Combined 1.10x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-18 (Est: $0.27)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.33 | $0.35 | +6.3% |
| 2025Q2 | $0.30 | $0.30 | -0.7% |
| 2025Q1 | $0.22 | $0.22 | +1.3% |
| 2024Q4 | $0.23 | $0.23 | -0.8% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_20*